<?xml version="1.0"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="en">
	<id>https://wikimd.org/index.php?action=history&amp;feed=atom&amp;title=Lixivaptan</id>
	<title>Lixivaptan - Revision history</title>
	<link rel="self" type="application/atom+xml" href="https://wikimd.org/index.php?action=history&amp;feed=atom&amp;title=Lixivaptan"/>
	<link rel="alternate" type="text/html" href="https://wikimd.org/index.php?title=Lixivaptan&amp;action=history"/>
	<updated>2026-04-27T01:04:20Z</updated>
	<subtitle>Revision history for this page on the wiki</subtitle>
	<generator>MediaWiki 1.44.2</generator>
	<entry>
		<id>https://wikimd.org/index.php?title=Lixivaptan&amp;diff=5369169&amp;oldid=prev</id>
		<title>Prab: CSV import</title>
		<link rel="alternate" type="text/html" href="https://wikimd.org/index.php?title=Lixivaptan&amp;diff=5369169&amp;oldid=prev"/>
		<updated>2024-03-06T04:58:08Z</updated>

		<summary type="html">&lt;p&gt;CSV import&lt;/p&gt;
&lt;p&gt;&lt;b&gt;New page&lt;/b&gt;&lt;/p&gt;&lt;div&gt;[[File:Lixivaptan.png|thumb|{{PAGENAME}}]]&amp;lt;br&amp;gt;&amp;#039;&amp;#039;&amp;#039;Lixivaptan&amp;#039;&amp;#039;&amp;#039; is a [[vasopressin receptor antagonist]] used in the treatment of [[hyponatremia]] (low blood sodium levels) associated with conditions like [[congestive heart failure]], [[cirrhosis]], and the [[syndrome of inappropriate antidiuretic hormone]] (SIADH). It is developed by [[Cardiokine Inc.]], a biopharmaceutical company focused on the discovery and development of new treatments for cardiovascular diseases.&lt;br /&gt;
&lt;br /&gt;
== Mechanism of Action ==&lt;br /&gt;
Lixivaptan works by blocking the action of [[vasopressin]], a hormone that regulates the body&amp;#039;s water balance. It specifically targets the [[vasopressin V2 receptor]], which is primarily found in the [[kidney]]s. By blocking this receptor, Lixivaptan increases the excretion of water in the urine, thereby increasing the concentration of sodium in the blood.&lt;br /&gt;
&lt;br /&gt;
== Clinical Trials ==&lt;br /&gt;
Lixivaptan has undergone several [[clinical trial]]s to evaluate its safety and efficacy. In a Phase III clinical trial, Lixivaptan was shown to be effective in correcting hyponatremia in patients with heart failure and SIADH. However, the drug has not yet received approval from the [[Food and Drug Administration]] (FDA).&lt;br /&gt;
&lt;br /&gt;
== Side Effects ==&lt;br /&gt;
Common side effects of Lixivaptan include dry mouth, thirst, and increased urination. In some cases, it may also cause a rapid increase in blood sodium levels, which can lead to serious complications such as [[osmotic demyelination syndrome]].&lt;br /&gt;
&lt;br /&gt;
== See Also ==&lt;br /&gt;
* [[Vasopressin receptor antagonist]]&lt;br /&gt;
* [[Hyponatremia]]&lt;br /&gt;
* [[Congestive heart failure]]&lt;br /&gt;
* [[Cirrhosis]]&lt;br /&gt;
* [[Syndrome of inappropriate antidiuretic hormone]]&lt;br /&gt;
&lt;br /&gt;
{{Medication-stub}}&lt;br /&gt;
[[Category:Drugs]]&lt;br /&gt;
[[Category:Vasopressin receptor antagonists]]&lt;br /&gt;
[[Category:Hyponatremia]]&lt;br /&gt;
[[Category:Cardiokine Inc.]]&lt;/div&gt;</summary>
		<author><name>Prab</name></author>
	</entry>
</feed>